Infermedica announced a $30 million Series B funding round, led by One Peak, and supported by previous investors: Karma Ventures, European Bank for Reconstruction and Development, Heal Capital, and Inovo Venture Partners.
The new investment – which follows a Series A funding round just over a year ago – brings the company's total funding to $44 million. The capital will be used to support Infermedica in tackling some of the biggest issues facing healthcare through further development of their Medical Guidance Platform (MGP) and adding new modules to cover the full primary care journey. Infermedica will also increase their global commercial presence and expand their international, remote-first team of industry and medical experts.
MGP leverages the same technology behind Infermedica's successful Symptom Checker tool, which has been used by over 10 million users globally, to triage patients to the right level of care. Infermedica plans to further develop the solution to enable seamless handover to providers, including EHR integration, as part of the intake process, as well as automating follow-ups to close the feedback loop. In the US alone, administrative simplification could reduce healthcare spending by over a quarter-trillion dollars ($265 billion) annually.
Founded in 2012 in Poland by Piotr Orzechowski (CEO), Infermedica's team grew by 80% in 2021 to 180 specialists – including physicians, data scientists, and engineers, and 2022 will see Infermedica on the trajectory to double their workforce yet again.
With the development of their Medical Guidance Platform underway, Infermedica is proud to be continuing their growth story as part of the One Peak investment portfolio.
Piotr Orzechowski, CEO and Co-Founder, Infermedica
We're thrilled to partner with One Peak as the lead investor for this round. From the moment we met, we were very impressed with One Peak's open and honest approach and felt that we share very similar values. One Peak is a high value-add partner for us with extensive experience in scaling B2B companies. I'm also thankful to our existing investors for their continued support and participation in our Series B round. To date, we've spent over 60,000 hours of physicians' work building one of the world's most advanced medical knowledge bases of diseases, symptoms, and risk factors.
